Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.10 USD
Change Today +0.03 / 1.45%
Volume 39.2K
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

biota pharmaceuticals inc (BOTA) Snapshot

Open
$2.11
Previous Close
$2.07
Day High
$2.12
Day Low
$2.07
52 Week High
07/30/14 - $3.44
52 Week Low
06/10/15 - $1.94
Market Cap
73.8M
Average Volume 10 Days
65.9K
EPS TTM
$-0.23
Shares Outstanding
35.1M
EX-Date
11/9/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTA PHARMACEUTICALS INC (BOTA)

Related News

No related news articles were found.

biota pharmaceuticals inc (BOTA) Related Businessweek News

No Related Businessweek News Found

biota pharmaceuticals inc (BOTA) Details

Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing oral, small molecule compounds to treat various respiratory-related viral infections. Its advanced clinical-stage program is laninamivir octanoate, a long-acting neuraminidase inhibitor for the treatment of influenza A and B. The company also develops vapendavir, which completed Phase II trials for the treatment of human rhinovirus infections in patients with moderate to severe asthma, as well as completed additional Phase 1 bioavailability and drug-drug interaction studies. In addition, it develops orally bioavailable F and non-F protein compounds for the treatment of respiratory syncytial virus infections in children, the elderly, and immune-compromised patients. Biota Pharmaceuticals, Inc. is headquartered in Alpharetta, Georgia.

66 Employees
Last Reported Date: 09/30/14

biota pharmaceuticals inc (BOTA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $408.0K
Executive Chairman
Total Annual Compensation: $525.0K
Compensation as of Fiscal Year 2014.

biota pharmaceuticals inc (BOTA) Key Developments

Biota Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015

Biota Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company reported net income of $1.2 million, or $0.03 per share, compared to $3.2 million or $0.09 per share, for the same quarter ended March 31, 2014. Total revenue was $5.9 million, compared to $29.5 million for the same quarter ended March 31, 2014. Income from operations was $1.1 million compared with $3.2 million a year ago. Income before tax was $1.2 million compared with $3.2 million a year ago. For the nine months, the company reported net income of $0.8 million, or $0.023 earnings per share, compared to a net loss of $0.08 million, or $0.03 loss per share, for the same period ended March 31, 2014. Total revenue was $20.5 million, compared to $60.3 million for the same period ended March 31, 2014. Income from operations was $0.5 million compared with loss from operations was $1.0 million a year ago. Income before tax was $0.8 million compared with loss before tax was $0.9 million a year ago.

Biota Pharmaceuticals, Inc. to Report Q3, 2015 Results on May 07, 2015

Biota Pharmaceuticals, Inc. announced that they will report Q3, 2015 results at 9:00 AM, US Eastern Standard Time on May 07, 2015

Biota Pharmaceuticals, Inc., Q3 2015 Earnings Call, May 07, 2015

Biota Pharmaceuticals, Inc., Q3 2015 Earnings Call, May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOTA:US $2.10 USD +0.03

BOTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Roche Holding AG SFr.266.30 CHF -0.10
View Industry Companies
 

Industry Analysis

BOTA

Industry Average

Valuation BOTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTA PHARMACEUTICALS INC, please visit www.biotapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.